Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Allarity Therapeutics Inc. Common Stock
ALLR | US
1.08
USD-0.02
-1.82%
ALLR | US
About Allarity Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
20/03/2026
Close
1.08
Open
1.10
High
1.12
Low
1.04
Allarity Therapeutics Inc. a clinical-stage biopharmaceutical company engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone) a selective microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis a liposomal formulation of cisplatin which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111 a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Boston Massachusetts.
View LessALLR | US
Risk
116.2
Sharpe
0.03
Luna's Score
48/100
Recommendation
Hold
Luna says (ALLR | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
127.8%1 month
116.2%3 months
89.2%6 months
86.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.12
Debt to equity
0.07
Debt to assets
0.04
Ent. to EBITDA
-0.08
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-16.89M
MarketCap
1.53M
MarketCap(USD)
1.53M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-121.82
Short ratio
0.15
Short perc.
10.03
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.42
Range1M
0.57
Range3M
0.65
Volumes: Market Activity
Rel. volume
0.90
Price X volume
191.38K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.08 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.12 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 89.17 | - | Riskier |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 1.53M | - | Emerging |
